Sarah Syeda, MD
Retina Specialist · Chicago, ILNPI 1447727847
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 27.3% of the total. Reporting peaked in 2021 at $2,196 and has fallen 82.6% since, to $383 in 2025.
Across 61 payments — averaging $104.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$2K
- Eyepoint US, Inc.$1K
- AbbVie$596
- Genentech USA, Inc.$219
- NEW World Medical,inc.$185
- plus $481 from 5 others
What the payments were for
- Consulting fees$1,10017%
- Travel & lodging$2,01032%
- Food & beverage$3,17050%
- Education$1002%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $1,741 |
| Alcon | 10 | $1,701 |
| Eyepoint US, Inc. | 5 | $1,458 |
| AbbVie(2 entities) | 13 | $596 |
| Genentech USA, Inc. | 2 | $219 |
| NEW World Medical,inc. | 1 | $185 |
| Regeneron Healthcare Solutions, Inc. | 3 | $156 |
| Sight Sciences, Inc. | 1 | $146 |
| Alimera Sciences, Inc. | 1 | $97 |
| Bausch & Lomb Americas Inc. | 1 | $53 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYP-1901$1,205
- STELLARIS$1,109
- Crystalens Accommodating IOL (AT-52AO)$1,109
- Trulign IOL$1,109
- Akreos AO IOL$1,109
- enVista MX60 IOL$1,109
- YUTIQ$231
- OMNI(R) SURGICAL SYSTEM (US)$146
- Centurion$144
- AcrySof IQ VIVITY$144
- SUSVIMO$140
- AcrySof IQ VIVITY IOL$136
- DURYSTA$116
- SIMBRINZA$115
- Rocklatan$115
- Rhopressa$115
- OZURDEX$110
How this compares
$6,380 in reported general payments places this provider in the 65th percentile of 70 retina specialist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 12 | $540 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chicago
- Rahul KomatiChicago$143K
- Veena RaijiChicago$69K
- Jeffrey ParnellChicago$27K
- Paulpoj ChiranandChicago$17K
- Henry FengChicago$16K
- Shaun IttiaraChicago$9K
- Saagar PanditChicago$6K
- Daniel BalikovChicago$3K
- Emily ShepherdChicago$3K
- John WilguckiChicago$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.